Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-β therapy in a patient with multiple sclerosis

Onkologie

Volumn 29, Issue 8-9, 2006, Pages 382-384

  Flörcken, Anne ^a   Denecke, Timm ^a   Kretzschmar, Albrecht ^b   Gollasch, Hella ^b   Reich, Gernot ^a   Westermann, Jörg ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Section of Pathology   (Germany)

Author keywords

Interferon ; Multiple sclerosis; Renal cell cancer

Indexed keywords

BETA INTERFERON;

ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG METASTASIS; MULTIPLE SCLEROSIS; NEPHRECTOMY;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-BETA; KIDNEY NEOPLASMS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEPHRECTOMY; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748558822     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094540     Document Type: Article

References (21)

1. Cohen HT, Mc Govern FJ: Renal cell carcinoma. N Engl J Med 2005;353:2477-90.
2. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant interleukin-2, recombinant human interferon alfa-2a, or both in metastastic renal-cell-carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338:1272-8.
3. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A: Canadian Urologic Oncology Group: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1265-71.
4. Kinney P, Triozzi P, Young D, Drago J, Behrens B, Wise H, Rinehart JJ: Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma. J Clin Oncol 1990;8(5):881-85.
5. The IFNB Multiple Sclerosis Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
6. Lublin F: History of modern multiple sclerosis therapy. J Neurol 2005;252(suppl 3):iii3-iii9.
7. Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R, Rotstein Z: Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005;89:265-70.
8. Atzpodien J, Lopez Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995;13(2):497-501.
9. Neidhart JA, Anderson SA, Harris JE, Rinehart JJ, Laszlo J, Dexeus FH, Einhorn LH, Trump DL, Benedetto PW, Tuttle RL: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991;9:832-6.
10. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M: Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44(3):406-13.
11. Durelli L, Bongioanni MR, Ferrero B, Ferri R, Imperiale D, Bradac GB, Bergui M, Geuna M, Bergamini L, Bergamasco B: Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996;47:123-29.
12. Van Osten BW, Uitdehaag BM, Barkhof F, Hartung HP, Wagstaff J, Polman CH: Interleukin-2 therapy does not exacerbate multiple sclerosis. Neurology 1997;49:633-4.
13. Kinkel RP, Rudick RA, Ransohoff RM: Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma. J Neurol Neurosurg Psychiatry 1997;62:100.
14. Tomer Y, Sherer Y, Shoenfeld Y: Autoantibodies, autoimmunity and cancer. Oncol Rep 1998;5:753-61.
15. Shoenfeld Y, Gershwin ME (eds): Cancer and Autoimmunity. Amsterdam, Elsevier, 2000, pp. 19-111.
16. Hughes GRV: Lupus patients are protected from cancer. Lupus 2001;10:833-34.
17. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J: Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999;17(2):529-33.
18. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
19. Koon H, Atkins M: Autoimmunity and immunotherapy for cancer. N Engl J Med 2006;354:758-60.
20. Komeda H, Horie M, Takahashi Y, Kobayashi S, Yamada S, Kuriyama M, Kawada Y: A case of renal cell carcinoma with lung metastases succesfully treated by interferon-beta. Hinyokika Kiyo 1989;35(4):637-41.
21. Scoponi C, Torresi U, Di Giuseppe M: Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report. Tumori 1995;81(3):201-3.